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Abstract 
Cocrystallization has emerged over the past decade as an attractive technique for modification of 
the physicochemical properties of compounds used as active pharmaceutical ingredients (APIs), 
complementing more traditional methods such as salt formation. Nutraceuticals, with associated 
health benefits and / or medicinal properties, are attractive as coformers due to their ready 
availability, known pharmacological profile and natural origin, in addition to offering a dual 
therapy approach. Successful studies of favorably altering the physicochemical properties of 
APIs through cocrystallization with nutraceuticals are highlighted in this review. Many of the 
key functional groups commonly seen in nutraceuticals (e.g. acids, phenols), underpin robust 
supramolecular synthons in crystal engineering. This review assesses the structural data available 
to date across a diverse range of nutraceuticals, both in pure form and in multicomponent 
materials, identifies the persistent supramolecular features present. This insight will ultimately 
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enable predictive and controlled assembly of functional materials incorporating nutraceuticals 
together with APIs. 
 
1. Introduction 
Cocrystallization can be defined as bringing together two or more discrete neutral molecular 
species in stoichiometric amounts in a crystalline lattice, without the breaking or making of 
covalent bonds, utilizing non-covalent forces of interaction such as hydrogen bonds, π-π 
interactions, and halogen bonds.1 These multi-component assemblies find immense use in 
various fields of research. Particularly within the pharmaceutical industry, they have been used 
for modifying the physicochemical properties of active pharmaceutical ingredients (APIs),2-9 
such as altering the aqueous solubility and/or dissolution rates,10-13 increasing the stability,14-16 
and improving the bioavailability.17-19 Cocrystallization is also being explored as an avenue for 
favorably altering the properties of agrochemicals.20 
 The choice of an appropriate coformer (cocrystal former) for APIs, which has an 
acceptable toxicity profile is an important aspect of co-crystallization in the pharmaceutical 
industry.21 In general, the coformers are selected from the lists of generally regarded as safe 
(GRAS)22 and pharmaceutically accepted salt formers.23 Since these compounds have been 
previously approved by FDA,21 utilizing them for cocrystallization reduces preclinical burden, 
toxicity risk and speed to clinical trials. Another class of compounds with an established safety 
record which can be used as viable candidates for cocrystallization in the pharmaceutical 
industry are the naturally occurring nutraceuticals. 
 Nutraceuticals, a term coined by DeFelice in 1989,24 can be defined as, “a food (or part of 
a food) that provides medical or health benefits, including the prevention and/or treatment of a 
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disease.”24 Zeisel proposed that this was too broad and there was a need to differentiate between 
functional foods, nutraceuticals, and dietary supplements.25 Accordingly, Kalra proposed the 
following: “a functional food which aids in the prevention and/or treatment of disease(s) and/or 
disorder(s) (except anemia).”26 Common classes of nutraceuticals include polyphenols (such as 
phenolic acids, coumarins, stilbenes, and flavonoids),27 and vitamins28 (Figure 1), which form 
the basis used for inclusion in this review. 
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Figure 1. Common classes of nutraceuticals. 
 The area of research on nutraceuticals is an evergrowing field, not only due to the 
potential health benefits associated with this class of compounds, but also because of their 
perceived therapeutic effect in multiple areas of medicine such as pain killers, cold and cough, 
sleeping disorders, digestion, and prevention of certain cancers.29,30 Also, the fact that they are 
patentable (meet the criteria required for patents), coupled with them being readily available over 
the counter, has led to an increased use of nutraceuticals as coformers in the pharmaceutical 
industry.31 The synergistic effect of nutraceuticals and APIs can be utilized to improve the poor 
physicochemical properties, such as stability,32 solubility33-35 and bioavailability,36 in a bid to 
assemble safe materials with improved properties. Also, the anti-oxidant properties of 
nutraceuticals can be used to impart stability to APIs that are prone to oxidation. Additionally, 
nutraceuticals with known health benefits but poor physicochemical properties can be co-
crystallized with GRAS acceptable coformers.37,38 
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 Cocrystallization of nutraceuticals is an important area of current research and holds 
tremendous potential for the future, as indicated by the rise in the number of cocrystals of 
nutraceuticals over the past few years based on the data obtained from the Cambridge Structural 
Database (CSD).39,40 Pharmaceutical cocrystals have been extensively reviewed.2,32,33,37 Despite 
the rapidly increasing number of crystallographic studies of nutraceuticals, and a review of their 
structural chemistry and behavioral patterns in the solid-state has not yet been clearly detailed. 
The one review to date on nutraceutical cococrytals exclusively focused on their 
physicochemical properties.31 In this review, we detail the different known forms of two 
different classes of nutraceuticals, namely polyphenols and vitamins. We examine the specific 
intra- and intermolecular interactions present in their crystal structures. We also analyze the 
findings in conjunction with the general solid-state behavior of the specific functional groups 
present within each class of nutraceuticals. Finally, we highlight some of the pharmaceutically 
relevant studies conducted over the past decade on improving the physicochemical properties of 
APIs via cocrystallization with nutraceuticals. 
 The Cambridge Structural Database (CSD) (ConQuest v. 1.16, May 2014 update) was 
used to obtain information about the crystal structures of the various nutraceuticals and the 
following filters were applied to the searches to limit the results: 3D coordinates determined, R 
factor < 7.5 %, no ions and only organics. The review has been organized around three 
categories: (i) phenolic acids (Figure 2); (ii) polyphenols including coumarin, stilbenes, 
flavonoids and lignans (Figure 3); and (iii) vitamins (Figure 4). The first two categories are 
members of the polyphenol family, differing only in the functional groups present in the 
molecules. Within each category, the data mined from the CSD was split up into six different 
groupings to facilitate the understanding of the nature of the intra- and intermolecular 
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interactions that are present in these molecules: (a) pure compounds; (b) hydrates; (c) cocrystals; 
(d) hydrated cocrystals; (e) salts; and (f) solvates (Table 1). 
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Figure 2. Structures of the phenolic acids examined. 
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Figure 3. Structures of the polyphenols examined, consisting of coumarin (8), stilbenes (9-10), 
flavonoids (11-21) and lignans (22-23). 
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Figure 4. Structures of the vitamins examined.  
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Table 1. Solid-state forms observed for the nutraceuticals. 
Molecule Structure Hydrated 
structures 
Cocrystals Hydrated 
cocrystals 
Salts Solvatesi 
Gallic acid, 1 3 5 9 5 4 2 
Protocatechuic acid, 2 1 3 3 0 1 2 
Vanillic acid, 3 1 0 4 0 0 0 
Caffeic acid, 4 1 0 0 1 0 0 
p-Coumaric acid, 5 1 0 6 1 1 1 
Sinapic acid, 6 0 0 0 0 0 1 
Ferulic acid, 7 1 0 2 2 1 0 
7-Hydroxy-6-
methoxycoumarin, 8 
2 0 0 0 0 0 
Resveratrol, 9 1 0 0 0 1 0 
Pterostilbene, 10 0 0 5 0 0 0 
Myricetin, 11 0 0 2 0 0 0 
Quercetin, 12 0 2 2 1 1 2 
Fisetin, 13 0 0 1 0 0 1 
Luteolin, 14 0 1 2 0 0 0 
Baicalein, 15 1 0 1 0 0 0 
Naringenin, 16 1 0 0 0 0 0 
Hesperetin, 17 1 1 0 0 2 0 
Genistein, 18 1 0 1 1 0 0 
Catechin, 19 1 1 0 2 0 2 
Epicatechin gallate, 20 0 0 0 2 0 0 
Epigallocatechin gallate, 21 1 1 0 7 1 2 
Pinoresinol, 22 2 0 0 0 0 2 
Podophyllotoxin, 23 2 0 0 0 0 3 
Retinal, 24 5 0 0 0 0 0 
Retinoic acid, 25 3 0 1 0 0 0 
Riboflavin, 26 0 0 0 2 2 0 
Pantothenic acid, 27 0 0 0 0 1 0 
Pyridoxine, 28 1 0 0 0 5 0 
Biotin, 29 1 0 0 0 0 0 
Ascorbic acid, 30 2 0 0 0 5 0 
Cholecalciferol, 31 1 0 2 0 0 0 
Ergocalciferol, 32 1 0 1 0 0 0 
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Folic acid, 33 0 1 0 0 0 0 
Menadione, 33 2 0 0 0 0 0 
i  Solvates of the nutraceuticals and their cocrystals are included in this category. 
2. Polyphenols 
Natural polyphenols are arguably the largest class of nutraceuticals which are commonly found 
in fruits, vegetables, tea, and barks of medicinal plants.27 Not only do they possess scavenging 
properties towards radical oxygen species, but are also capable of complexing with proteins.41 As 
a result, they are interesting candidates for the treatment of various symptoms and diseases such 
as inflammation or cancer, and for anti-ageing purposes in cosmetic formulations.42,43 However, 
their use in any pharmaceutical applications is limited by their low aqueous solubility and poor 
stability, generally being sensitivity to light and heat.27 Different techniques such as 
encapsulation and cocrystallization have been employed to improve the physicochemical 
properties of polyphenols, to aid in increasing their use in the pharmaceutical industry. 27  
2.1. Phenolic acids 
 The crystal structures for all the phenolic acids except sinapic acid are known. In two 
cases (1-2), hydrated structures of the molecules by themselves are observed. A total of 24 
cocrystals were observed for these molecules, with a maximum of nine cocrystals observed for 
gallic acid (1). There were nine structures where the nutraceuticals formed hydrated cocrystals in 
the presence of other hydrogen-bond donor or acceptor molecules, whereas in four cases, the 
formation of salts was observed (1-2, 5, 7). The crystal structures were examined in detail and 
are described below. 
 Focusing initially on gallic acid, the simple planar compound combining carboxylic acid 
and phenolic moieties displays remarkable versatility in terms of its co-crystallization behavior 
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with co-formers or indeed solvates. The solid state structure of gallic acid on its own displays 
characteristic chains of R22(8) dimers (using graph set notation)44,45 linked through the p-hydroxy 
groups with interlinking orthogonal chains in 3-D through the remaining phenolic units 
(IJUMEG04) (Figure 5).46 
 
Figure 5. The structure of gallic acid (IJUMEG04). 46 
 Interestingly, in the many hydrate forms while the R22(8) dimer is retained in some of the 
structures, it is absent in others, and versatile hydrogen bonds to water through the phenolic 
groups are clearly feasible in the solid state.46-49 Thus, the multiple hydrogen bonds between the 
phenols and the water molecules can compensate for the carboxylic acid dimer. The existence of 
5 hydrates of gallic acid (KONTIQ, KONTIQ01, KONTIQ04, KONTIQ05, and KONTIQ06)46-49 
and 5 polymorphs of the acetamide-gallic acid cocrystal (1:1 in PEFGEO, PEFGEO01, 
PEFGEO02 and PEFGEO03; 1:3 in PEFGIS)50 in which a blend of acid-acid and acid-amide 
dimer is seen highlights the flexibility of gallic acid as a co-former for APIs, and this is further 
evidenced by co-crystals of gallic acid with oxiracetam (1:1 in ZEBXEL and ZEBXIP)51 (Figure 
6) and isoniazid (1:1 in LODHOD)52 (Figure 7). Of the co-crystals observed, the intermolecular 
interactions such as acid-amide, acid-pyridyl, acid-heterocyclic amine, acid-N-oxide, clearly 
compete for the acid-acid homodimer, as would be expected based on Etter’s rules.44,53-55 In 
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other cases, the acid-acid dimer persists with the co-former forming hydrogen bonds to the 
phenol moieties essentially capping the dimer motifs. 
 
Figure 6. The structure of 1:1 gallic acid-oxiracetam cocrystal (ZEBXEL).51 
 
Figure 7. The structure of 1:1 gallic acid-isoniazid cocrystal (LODHOD).52 
 There are ten known crystal structures containing protocatechuic acid (see Table 1). An 
examination of the structure of protocatechuic acid by itself reveals that the acid moiety is 
forming the well-known R22(8) acid-acid dimer which is capped on both ends by a phenolic 
substituent of protocatechuic acid via O-H…O hydrogen bonds (WUYNUA) (Figure 8).56 At the 
other end six phenolic substituents from four adjacent protocatechuic acid molecules are forming 
an extended R24(14) supramolecular synthon,57 thus giving rise to an extended architecture. 
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Figure 8. The structure of protocatechuic acid (WUYNUA).56 
 There are three polymorphs of protocatechuic acid monohydrate (BIJDON03, BIJDON04 
and BIJDON05), and they all retain identical supramolecular motifs to the structure of 
protocatechuic acid by itself. The expected R22(8) acid-acid dimer is retained, whereas the phenol 
groups capping the acid dimer has been replaced by water molecules capping the acid-acid dimer 
(Figure 9).56,58,59 In one of the polymorphs two water molecules and four phenolic substituents 
from two adjacent protocatechuic acid molecules are forming a similar R24(14) supramolecular 
synthon to the one observed in protocatechuic acid (BIJDON03).58 
 
Figure 9. The structure of protocatechuic acid monohydrate (BIJDON03).58 
 An examination of the structure of protocatechuic acid-oxiracetam (1:1) cocrystals 
reveals that the acid-acid homodimer has been replaced by the acid-amide heterodimer 
(ZEBXOV and ZEBXUB) (Figure 10).51 Also, one of the phenolic substituents is extending the 
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motif into 1-D ribbons via O-H…O hydrogen bonds between the phenol group of the 
protocatechuic acid and the alcohol group of the oxiracetam. Furthermore, the other phenolic 
substituent caps the acid-amide dimer via phenol O-H…O=C carbonyl hydrogen bonds, where 
the supramolecular architecture is further extended via anti-amide N-H…O alcohol 
intermolecular interactions between two oxiracetam molecules. 
 
Figure 10. The structure of 1:1 protocatechuic acid-oxiracetam cocrystal (ZEBXOV).51 
 The structure of vanillic acid displays the familiar acid-acid homodimer and the only 
phenolic substituent caps the hydroxyl moiety of the acid-acid dimer on both ends, thus giving 
rise to 2-D sheets (CEHGUS) (Figure 11).60 
 
Figure 11. The structure of vanillic acid (CEHGUS).60 
 The vanillic acid-pyrazine-2-carboxamide (1:1) cocrystal surprisingly displays separate 
acid-acid and amide-amide homodimers for vanillic acid and pyrazine-2-carboxamide 
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respectively (REBXED), Figure 12, in contrast to the more usual acid-amide heterodimer. 61 The 
two discrete dimers are interlinked via phenol O-H…Narom hydrogen bonds and a R22(10) ring 
formed via anti-amide N-H…Narom hydrogen bonds between two adjacent pyrazine-2-
carboxamide molecules, thus giving rise to a supramolecular architecture resembling 2-D sheets. 
 
Figure 12. The structure of 1:1 vanillic acid-pyrazine-2-carboxamide cocrystal (REBXED). 61 
 The 1:1 cocrystal of vanillic acid with the API ethenzamide shows the formation of the 
favored acid-amide heterodimer with the only phenolic substituent on vanillic acid capping the 
carbonyl of the acid moiety in the acid-amide dimer (REHSII) (Figure 13).62 A similar 
heterodimer supramolecular motif is also observed in the cocrystal between vanillic acid and 4-
chloro-3,5-dimethyl-1H-pyrazole (1:1), wherein the acid moiety is hydrogen bonded to the 
pyrazole moiety forming an R22(7) dimer with the phenolic substituent capping the acid carbonyl 
group (PEKWUZ). 63 
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Figure 13. The structure of 1:1 vanillic acid-ethenzamide cocrystal (REHSII). 62 
 Another novel 1:1 cocrystal of vanillic acid with the bioactive herbal medicine 
andrographolide displays the hydroxy lactone moiety of adjacent andrographolide molecules 
connected through strong alcohol O-H…O=C hydrogen bonds leading to the formation of 1-D 
tapes (GIHCIL) (Figure 14).64 Vanillic acid molecules connect these 1-D tapes via phenol/acid 
O-H…O alcohol hydrogen bonds on both sides. Notably, the acid-acid dimer is absent in this 
supramolecular architecture. 
 
Figure 14. The structure of 1:1 vanillic acid-andrographolide cocrystal (GIHCIL). 64 
 The structure of caffeic acid displays identical motifs to those observed in gallic acid and 
protocatechuic acid, wherein the expected acid-acid homodimer is retained with one of the 
phenolic substituents responsible for satisfying the carbonyl group of the acid-acid dimer on both 
sides (FESNOG01) (Figure 15).65 The remaining phenolic substituent forms bifurcated hydrogen 
bonds with two phenolic substituents of an adjacent caffeic acid molecule. 
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Figure 15. The structure of caffeic acid (FESNOG01).65 
 The structure of caffeic acid-nicotinamide (1:1) monohydrate also displays the preferred 
acid-amide heterodimer, where the two phenolic substituents of caffeic acid on adjacent 
molecules are involved in forming a R22(10) supramolecular homosynthon, thus giving rise to a 2-
D sheet like architecture (MUPMOA) (Figure 16).66 This is further extended to a 3-D 
supramolecular architecture due to the water molecules acting as a bridge between two adjacent 
layers via water O-H…Narom and water O-H…O phenol hydrogen bonds. 
 
Figure 16. The structure of caffeic acid-nicotinamide (1:1) monohydrate (MUPMOA).66 
 There are ten known crystal structures containing p-coumaric acid (see Table 1). An 
examination of the structure of p-coumaric acid by itself reveals two interesting features: (a) 
presence of the R22(8) acid-acid homodimer; and (b) formation of the phenol C(2) catemeric 
chains (COUMAC01) (Figure 17).67 A notable observation here is the absence of the discrete 
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phenol O-H…O=C hydrogen bonds which are prevalent in the structures of the other phenolic 
acids (1-4, 7). 
 
Figure 17. The structure of p-coumaric acid (COUMAC01).67 
 The acid-acid homodimer in p-coumaric acid has been replaced by acid O-H…Narom 
hydrogen bonds in the structure of p-coumaric acid-caffeine (1:1) cocrystal (IJEZUT) (Figure 
18).68 At the other end of the molecule the phenolic substituent is forming intermolecular 
hydrogen bonds with one of the carbonyl groups on caffeine, thus giving rise to 1-D chains. The 
corresponding p-coumaric acid-caffeine (1:2) hydrated complex retains the same supramolecular 
motifs in its structure, with the only difference being the absence of 1-D chain like architecture 
in the hydrated complex (IJIBAF).68 
 
Figure 18. The structure of p-coumaric acid-caffeine (1:1) cocrystal (IJEZUT).68 
 The two known polymorphs of the 1:1 cocrystal of p-coumaric acid with the respiratory 
drug theophylline display synthon polymorphism, where both Form I (IJIBEJ) and II (IJIBEJ01) 
possess a R22(9) carboxylic acid-imidazole heterosynthon.68 However, in Form I the phenolic 
substituent on p-coumaric acid is forming hydrogen bonds with the remaining carbonyl group on 
 18 
theophylline (Figure 19), whereas, in Form II the phenolic substituent on p-coumaric acid is 
hydrogen bonded to the imidazole nitrogen atom of theophylline (Figure 20). 
 
Figure 19. The structure of p-coumaric acid-theophylline (1:1) cocrystal, Form I (IJIBEJ).68 
 
Figure 20. The structure of p-coumaric acid-theophylline (1:1) cocrystal, Form II (IJIBEJ01).68 
 The structure of the 1:1 cocrystal of p-coumaric acid with the API isonicotinohydrazide 
displays the expected R22(7) acid-hydrazide heterosynthon (PEHFUF) (Figure 21).69 This motif is 
extended into 1-D ribbons by hydrogen bonds between the phenolic substituent of p-coumaric 
acid and the aromatic nitrogen atom of isonicotinohydrazide. Furthermore, adjacent ribbons are 
interlinked via hydrogen bonds between the anti-hydrazide hydrogen atom and the carbonyl of 
the acid, thus giving rise to a 2-D sheet like supramolecular architecture. 
 19 
 
Figure 21. The structure of p-coumaric acid-isonicotinohydrazide (1:1) cocrystal (PEHFUF).69 
 There are three polymorphs of the 1:1 cocrystal of p-coumaric acid with nicotinamide, of 
which only Forms I (SOLBEC01) and III (SOLBEC) have been characterized by single crystal 
X-ray diffraction.70 Both of these forms display identical primary intermolecular interactions, i.e. 
the preferred acid-amide heterosynthon coupled with the phenol O-H…Narom hydrogen bonds are 
responsible for the formation of 1-D chains in both cases. The striking difference between the 
two structures is the crosslinking hydrogen bonds present between adjacent 1-D chains. In Form 
I the anti-amide hydrogen atom is hydrogen bonded to the hydroxyl oxygen atom of the acid 
moiety (Figure 22), whereas in Form III two anti-amide hydrogen atoms coupled with the 
carbonyl oxygen atoms of the acid moiety are forming a complementary R24(8) supramolecular 
synthon (Figure 23).70 
 
Figure 22. The structure of p-coumaric acid-nicotinamide cocrystal (Form I) (SOLBEC01).70 
 20 
 
Figure 23. The structure of p-coumaric acid-nicotinamide cocrystal (Form III) (SOLBEC).70 
 The structure of ferulic acid displays identical supramolecular motifs to those observed in 
vanillic acid, i.e. the acid-acid homodimer is retained along with the hydrogen bond between the 
phenolic substituent and the hydroxy moiety of an adjacent acid-acid dimer (GASVOL01) 
(Figure 24).71 The similarity between the two acids can be attributed to the presence of an 
identical aromatic backbone in both molecules (meta methoxy and para hydroxy substituents). 
 
Figure 24. The structure of ferulic acid (GASVOL01).71 
 There are two cocrystals of ferulic acid (IKAFAC and BUFQAO)72,73 of which the 1:1:1 
ternary cocrystal of ferulic acid with 3,5-dinitrobenzoic acid and isonicotinamide is a classic 
example of Etter’s rules in hydrogen bonding being used to assemble complex supramolecular 
architectures (BUFQAO). The primary hydrogen bond donor is the acid moiety of 3,5-
dinitrobenzoic acid which is hydrogen bonding with the primary hydrogen bond acceptor i.e. the 
pyridyl nitrogen atom of isonicotinamide (O-H…N 1.366 Å, HO…N 2.559 Å, O-H…N 174.59º) 
(Figure 25).72 The secondary hydrogen bond donor and acceptor are the acid moiety of ferulic 
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acid and the amide end of isonicotinamide which are forming an acid-amide heterodimer (O-
H…O 1.658 Å, HO…O 2.636 Å, O-H…O 171.10º; N-H…O 1.827 Å, HN…O 2.819 Å, N-H…O 
167.71º). The extended architecture is assembled via ferulic acid phenol O-H…O=C carbonyl 
3,5-dinitrobenzoic acid (O-H…O 1.908 Å, HO…O 2.714 Å, O-H…O 128.58º) and anti-amide N-
H…O nitro hydrogen bonds. The selectivity in terms of hydrogen bonds is also reflected in the 
observed hydrogen bonding distances. 
 
Figure 25. The structure of 1:1:1 ferulic acid-isonicotinamide-3,5-dinitrobenzoic acid ternary 
cocrystal (BUFQAO).72 
2.1.1 Common features observed for phenolic acids  
Some common structural features that are observed in the structures of different phenolic acids 
along with the robust intermolecular interactions, Table 2, which are present in these crystal 
structures are outlined in this section.  
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Table 2. The most common intra- and intermolecular interactions observed in the phenolic acids 
have been organized in four categories: (i) acids as donors; (ii) acids as acceptors; (iii) phenols as 
donors; and (iv) phenols as acceptors. 
Type of Interaction Structure Hydrated 
structures 
Cocrystals Hydrated 
cocrystals 
Salts Solvates 
Acids as donors 
O
O
H
O
O
H
 
1(3), 2, 3, 
4, 5, 7 
1(3), 2(3) 1(2), 3, 7 1 1(2), 2 2, 6 
O
O
H
N
O
H
H
 
  1(3), 2(2), 
3, 5(2), 7 
1, 4, 7(2)   
O
O
H N
 
  1, 3, 5, 7 1(2), 5  1(2), 2, 
5 
Acids as acceptors 
O
H
O
O
H  
1(3), 2, 4 1(5) 1(3), 2(2), 
3(2), 7 
1 1 1(2), 2 
O
O
H
HN
H
O
 
  1(4) 1   
H O
H
O
O
H  
 2(3)  1 1  
Phenols as donors 
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O
H
O
H  
1(3), 2, 4, 
5 
1(4), 2(2) 1(5), 2 1, 4  1, 2(2) 
O
H
O
H  
  2(2), 3   1, 5, 6 
O
H
O
N
H
H
 
  1(7) 1(2)   
O
H
N
 
  1, 3, 5(4), 
7 
1(2)  1 
O
H
O
 
  1(2) 1(2)   
O
H
O H
H  
 1(5), 2(3)  1(5), 4, 
7(2) 
1(3), 2, 
5 
5 
O
H
O
O
 
    1(4), 2, 
7 
 
Phenols as acceptors 
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H O
H
O
H  
 1(5), 2(3)  1(3), 4, 7 1(2), 2, 
7 
 
Numbers in brackets indicate the number of times the particular interaction is observed in the 
appropriate compound (as identified in Figure 2). 
 It is observed that the structures of all the phenolic acids as pure compounds display three 
characteristic types of intermolecular interactions: (a) acid…acid dimer (1-5, 7); (b) phenol O-
H…O phenol hydrogen bonds (1-2, 4-5); and (c) phenol O-H…O=C acid discrete hydrogen bonds 
(1-2, 4) (Figure 26). 
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Figure 26. The three common hydrogen bonding motifs observed in phenolic acids: (a) 
acid…acid dimer (left); phenol O-H…O phenol (middle) and phenol O-H…O=C acid discrete 
hydrogen bonds (right). 
 These observations are in accordance with the data from the CSD on carboxylic acids,74 
where in the absence of competing hydrogen bond donors or acceptors, the carboxylic acid 
moiety will preferentially form the homodimer supramolecular synthon (Table 2). Similarly, the 
phenolic substituents exhibit the common motifs associated with phenols such as the phenol O-
H…O phenol homosynthon or the phenol O-H…O=C acid heterosynthon.75-77 A notable 
observation is that as the number of phenolic substituents on the phenolic acid backbone 
increase, other hydrogen bonding synthons characteristic of the phenol functional group become 
more prevalent and all the phenolic substituents are involved in hydrogen bonding. For example, 
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a higher number of hydrates are seen for gallic acid (1) and protocatechuic acid (2) which have 
three and two phenolic substituents respectively. This can be a direct consequence of an increase 
in the number of unsatisfied hydrogen bond donors and acceptors as the number of phenolic 
substituents increases, and thus other intermolecular interactions such as phenol O-H…O water 
and water O-H…O phenol hydrogen bonds are seen. 
 Upon cocrystallization the acid-acid homodimer gives way to the favored heteromeric 
synthons such as acid-amide and acid-Narom supramolecular motifs, whereas the phenolic 
substituents are involved in phenol O-H…O phenol, phenol O-H…O=C acid, phenol O-H…O=C 
amide and phenol O-H…Narom hydrogen bonds.75,78,79 The observed motifs for the acid and phenol 
moieties are representative of the coformer used and the functional groups present in the 
coformers.  
Consideration of the calculated molecular electrostatic potentials (MEPs) for the phenolic 
acids should allow for a better understanding of the hydrogen bonding capability of acids and 
phenols.80 Accordingly, charge calculations were performed, using Spartan’14 (Wavefunction, 
Inc. Irvine, CA). All molecules were energy optimized using DFT B3LYP/6-31+G* ab initio 
calculations, with the maxima and minima in the electrostatic potential surface (0.002 e au-1 iso-
surface) determined using a positive point charge in vacuum as a probe. Based on the calculated 
MEPs, the phenols are a more effective hydrogen bond donor than the acid moiety as observed in 
compounds 1-5, see Figure 27, and thus in a competitive molecular recognition situation should 
compete effectively with acids for available hydrogen bond acceptors. The two exceptions are 6-
7, where the presence of the electron donating methoxy groups on the aromatic ring are 
responsible for decreasing the calculated MEP values of the phenolic moiety. In the two 
examples of cocrystals of phenolic acids with either a symmetric ditopic hydrogen bond acceptor 
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(WAJWAH) (acid O-H…O 1.81 Å, HO…O 2.624(5) Å, O-H…O 175.4º; phenol O-H…O 1.81 Å, 
HO…O 2.629(4) Å, O-H…O 177.3º),81 or an asymmetric ditopic hydrogen bond acceptor 
(WAJXAI) (acid O-H…O 1.84 Å, HO…O 2.655(2) Å, O-H…O 173.7º; phenol O-H…O 1.84 Å, 
HO…O 2.647(3) Å, O-H…O 166.0º; phenol O-H…N 2.00 Å, HO…N 2.707(3) Å, O-H…N 
144.5º),81 the two functional groups compete with each other for the available hydrogen bond 
acceptors (also reflected in the observed hydrogen bonding distances), and thus hydrogen 
bonding occurs with both ends of the molecule. A more detailed study with multiple monotopic / 
ditopic symmetric / ditopic asymmetric hydrogen bond acceptors is required to shed further light 
on the existing competition in hydrogen bonding between phenols and acids, and correlate the 
observed interactions with the predicted interactions based on the calculated MEPs. 
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Figure 27. The calculated molecular electrostatic potentials (kJ mol-1) for the phenolic acids. 
Blue = positive potential, red = negative potential. 
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2.2. Polyphenols (including coumarin, stilbenes, flavonoids and lignans) 
Polyphenols such as coumarins, stilbenes, flavonoids and lignans are widely found in the plant 
kingdom.82 They are very potent antioxidants in vitro, and as a result have been known to exhibit 
several biological effects such as protection against cardiovascular diseases, anti-hepatotoxic, 
anti-inflammatory and anti-ulcer activities.83 This has led to an increased interest in the 
pharmaceutical properties and applications of polyphenols over the past decade. Sixteen different 
molecules have been explored in this category, of which one is a coumarin (8), two are stilbenes 
(9-10), eleven flavonoids [three flavonols (11-13), two flavones (14-15), two flavanones (16-17), 
one isoflavone (18), three flavanols/catechins (19-21)], and finally two lignans (22-23) have been 
included (Figure 3). 
 7-Hydroxy-6-methoxycoumarin is a simple planar molecule with a single hydrogen bond 
donor in the form of the phenolic substituent. Both polymorphs exhibit the same 1-D chains via 
phenol O-H…O=C hydrogen bonds (HXMCOU and HXMCOU01) (Figure 28).84,85 
 
Figure 28. One polymorph of 7-hydroxy-6-methoxycoumarin (HXMCOU).84 
 There are two known crystal structures containing resveratrol (see Table 1). An 
examination of the structure of resveratrol by itself reveals the formation of multiple phenol O-
H…O phenol C(2) catemeric chains between the three phenolic substituents in the absence of any 
other hydrogen bond donors or acceptors (DALGON) (Figure 29).86 
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Figure 29. The structure of resveratrol (DALGON).86 
 The use of the planar pterostilbene molecule as a potential coformer in pharmaceutical 
cocrystallization is highlighted by the existence of five known cocrystals of pterostilbene with 
different APIs. Cocrystal formation in the case of the pterostilbene-piperazine (2:1) cocrystal is 
driven by two distinct phenol O-H…N piperazine hydrogen bonded interactions between adjacent 
pterostilbene and piperazine molecules (OWAVUE) (Figure 30).87 
 
Figure 30. The structure of 2:1 pterostilbene-piperazine cocrystal (OWAVUE).87 
 The structure of pterostilbene-glutaric acid (1:1) cocrystal displays two interesting 
features (OWAWAL). First, one of the acid moiety of the dicarboxylic acid is forming an 
expected R22(8) acid-acid homodimer (Figure 31).87 Second, the other acid moiety of two glutaric 
acid molecules coupled with the phenolic substituent of two adjacent pterostilbene molecules are 
forming a tetrameric acid-phenol-acid-phenol R44(12) supramolecular heterosynthon. There are 
160 occurrences of this motif in the CSD.39,40 
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Figure 31. The structure of the pterostilbene-glutaric acid cocrystal (OWAWAL).87 
 The structure of two polymorphs of the pterostilbene-caffeine (1:1) cocrystals display the 
expected phenol O-H…O=C caffeine intermolecular interactions as pterostilbene is a single point 
hydrogen bond donor and caffeine is a hydrogen bond acceptor (YABHAM and YABHAM01) 
(Figure 32).88 In comparison, the pterostilbene-carbamazepine (1:1) cocrystal displays the amide-
amide homodimer for carbamazepine, where, in the absence of any other suitable hydrogen bond 
acceptors, the phenolic substituent of pterostilbene is satisfying the carbonyl groups of the 
amide-amide dimer on both ends via phenol O-H…O=C amide hydrogen bonds (YABHIU) 
(Figure 33).88 
 
Figure 32. The structure of pterostilbene-caffeine (1:1) cocrystal (YABHAM).88 
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Figure 33. The structure of pterostilbene-carbamazepine (1:1) cocrystal (YABHIU).88 
 It is important to know the structural classification of flavonoids to gain a better 
understanding of the type and position of the hydrogen-bonded interactions observed in the 
structures. All flavonoids have a common C6-C3-C6 phenyl-benzopyran backbone, where the 
position of the phenyl ring relative to the benzopyran moiety allows for a clear distinction to be 
made between flavonoids (2-phenyl-benzopyrans), isoflavonoids (3-phenyl-benzopyrans) and 
neoflavonoids (4-phenyl-benzopyrans) (Figure 34).89,90 These are further subdivided into groups 
based on the central ring oxidation and on the presence of hydroxyl groups. The most common 
flavonoids are flavonols (flavones with a 3-OH group), flavones (with a C2-C3 double bond and 
a C4-oxo functionality), and flavanones (with a C2-C3 single bond), whereas abundant 
isoflavonoids include isoflavones (the analogue of flavones). 
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Figure 34. Structural backbone of the three main flavonoid groups: (a) flavan; (b) isoflavan; and 
(c) neoflavan. These can be classified into the common flavonoid classes: (d) flavonol; (e) 
flavone; (f) flavanone; (g) isoflavone; and (h) flavanol. Atom numbering and ring nomenclature 
are also included. 
 The 1:2 cocrystal of myricetin with triphenylphosphine oxide displays the expected 
intramolecular O-H…O=C hydrogen bond between the phenolic moiety on the benzene ring and 
the carbonyl on the pyrone ring (PILCIW) (Figure 35).91 The phenolic substituents on ring B are 
forming two discrete phenol O-H…O=P hydrogen bonds which act as the driving force for 
cocrystal formation, whereas the phenolic substituent on ring A is hydrogen-bonded to the 
phenol moiety on ring B. Interestingly, the hydroxy substituent α to the carbonyl group on ring C 
is not involved in any structure defining hydrogen bonds. 
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Figure 35. The structure of myricetin-triphenylphosphine oxide cocrystal (PILCIW).91 
 The structure of the 1:1 cocrystal of myricetin with the API piracetam reveals that the 
intramolecular hydrogen bond between substituents on ring A and C is retained, and cocrystal 
formation is accomplished by hydrogen bonds between ring B phenol O-H…O=C amide and 
amide N-H…O phenol (α to the carbonyl on pyrone ring, ring C) moieties resulting in a R22(12) 
molecular heterodimer (FIXROV) (Figure 36).92 The heterodimers are extended into ribbons via 
ring B phenol O-H…O=C cyclic carbonyl of piracetam and amide (second hydrogen atom) N-
H…O phenol (ring B) intermolecular interactions. The remaining phenolic substituents on 
myricetin help assemble the 3-D supramolecular architecture by phenol O-H…O=C cyclic 
carbonyl of piracetam, phenol O-H…O phenol and phenol O-H…O=C amide hydrogen bonds. 
 
Figure 36. The structure of myricetin-piracetam cocrystal (FIXROV).92 
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 There are eight known structures involving quercetin (see Table 1). The structure of 
quercetin monohydrate reveals four key features (AKIJEK) (Figure 37).93 The first is an 
intramolecular O-H…O=C hydrogen bond between the phenolic moiety on ring A and the 
carbonyl group on ring C. Second, a dimer motif between adjacent quercetin molecules via O-
H…O=C hydrogen bonds between the carbonyl group on ring C and the hydroxy group α to the 
carbonyl group is observed. Third, two of the phenolic substituents on ring A and B are forming 
orthogonal chains via phenol O-H…O phenol intermolecular hydrogen bonds. Last, the water 
molecule is interacting with the remaining phenolic substituent on ring B via phenol O-H…O 
water hydrogen bonds as well as with the carbonyl group on ring C, thus forming a bridge 
between two layers. 
 
Figure 37. The structure of quercetin monohydrate (AKIJEK).93 
 Interestingly, in the structure of quercetin dihydrate the intramolecular hydrogen bond 
has been retained, whereas the dimer motif and the 1-D chain has given way to multiple water O-
H…O phenol and phenol O-H…O water hydrogen bonds (FEFBEX01).94 The 2:3 cocrystal of 
quercetin with 1,4-diazabicyclo[2.2.2]octane (DABCO) shows the expected intramolecular 
hydrogen bond as well as the hydrogen-bonded dimer motif between adjacent quercetin 
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molecules (COLHIV). The three remaining phenolic substituents on rings A and B are hydrogen 
bonding with the nitrogen atoms of three different DABCO molecules (Figure 38).95 
 
Figure 38. The structure of quercetin-DABCO cocrystal (COLHIV).95 
 In comparison, the quercetin-isonicotinamide cocrystal retains only the expected 
intramolecular hydrogen bond, whereas the flavonoid dimer motif as observed in the quercetin-
DABCO cocrystal is absent. The catechol end of quercetin (ring B) is forming a R22(10) 
supramolecular homodimer, while the dimer is flanked on either sides by two R33(8) dimers 
formed via phenol O-H…O=C amide and amide N-H…O phenol hydrogen bonds (Figure 39).96 
This four component supramolecular assembly between two quercetin and two isonicotinamide 
molecules can also be described by the R44(18) graph set. Furthermore, this assembly is extended 
into 1-D ribbons via ring A phenol O-H…Narom intermolecular interactions. Interestingly, the 
hydroxy substituent α to the carbonyl group on ring C of quercetin is not involved in any 
structure-defining hydrogen bonds, and the carbonyl group is capped by the anti-amide hydrogen 
atom. Multiple amide N-H…O=C quercetin hydrogen bonds are responsible for the generation of 
the 2-D layered architecture. 
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Figure 39. The structure of quercetin-isonicotinamide cocrystal.96 
 The structure of quercetin-theobromine (1:1) dihydrate retains the expected 
intramolecular hydrogen bond along with the dimer motif (MUPPOD) (Figure 40).66 The amide 
moiety on theobromine is forming an R22(8) amide-amide homodimer, while adjacent quercetin 
dimers and theobromine dimers are interlinked via ring B phenol O-H…O=C theobromine, ring A 
phenol O-H…O water, and water O-H…Narom hydrogen bonds (water molecules act as bridges). 
 
Figure 40. The structure of quercetin-theobromine dihydrate (MUPPOD).66 
 The fisetin-isonicotinamide (1:1) cocrystal has identical supramolecular motifs to that 
seen in the quercetin-isonicotinamide cocrystal, wherein the R22(10) catechol homodimer is 
flanked on either sides by two R33(8) phenol-amide heterodimers (ZIKNOY) (Figure 41).97 
Extended 2-D sheets are formed via multiple ring A phenol O-H…Narom and amide N-H…O=C 
carbonyl (ring C) hydrogen bonds. Interestingly, the difference (in terms of supramolecular 
synthons) between these cocrystals is the presence of the flavonoid dimer motif in the fisetin-
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isonicotinamide cocrystal (extends the 2-D sheets into a 3-D architecture), which is clearly 
absent in the quercetin-isonicotinamide, even though an hydroxy group α to the carbonyl group 
exists on the quercetin backbone. In contrast, the R22(10) catechol homodimer flanked by the 
R33(8) phenol-amide heterodimer motif is absent in fisetin-nicotinamide (1:2) ethanol hemisolvate 
(ZIKPAM) (Figure 42).97 The flavonoid dimer motif is retained and the supramolecular 
architecture is assembled via ring B phenol O-H…Narom, ring A phenol O-H…O=C nicotinamide, 
amide N-H…O=C amide [amide C(4) chain], and amide N-H…O phenol (ring A) hydrogen 
bonds. 
 
Figure 41. The structure of fisetin-isonicotinamide cocrystal (ZIKNOY).97 
 
Figure 42. The structure of fisetin-nicotinamide ethanol hemisolvate (ZIKPAM).97 
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 An examination of the structure of luteolin hemihydrate reveals three key features 
(OJEQUP) (Figure 43).98 First, the intramolecular hydrogen bond between the phenolic 
substituent (ring A) and the carbonyl group (ring C), as observed in flavonoids 11-12, 14-18, 
persists. Second, in the absence of the hydroxy substituent α to the carbonyl group on ring C 
(with the result that dimer formation is not feasible) an intermolecular O-H…O=C hydrogen bond 
between adjacent luteolin molecules is observed. Third, the remaining phenolic substituents on 
ring A and B form multiple phenol O-H…O phenol hydrogen bonds, thus extending the 
supramolecular architecture. 
 
Figure 43. The structure of luteolin hemihydrate (OJEQUP).98 
 Although polymorphic cocrystals of APIs are not uncommon,88,99,100 the first report of 
flavonoid polymorphic cocrystals was by Sowa et al.,97 wherein two polymorphs of 1:1 luteolin-
isonicotinamide cocrystal were observed. Form I has an identical crystal structure to the 
quercetin-isonicotinamide and fisetin-isonicotinamide cocrystals, wherein the R22(10) catechol 
homodimer is flanked on either sides by two R33(8) phenol-amide heterodimers (ZIKPUG) 
(Figure 44).97 Furthermore, the extended 2-D sheet like architecture is formed via multiple ring 
A phenol O-H…Narom and amide N-H…O=C carbonyl (ring C) intermolecular hydrogen bonds. In 
contrast, Form II does not form the catechol homodimer motif in the solid-state, and instead 
cocrystal formation is driven by ring A phenol O-H…Narom, amide N-H…O phenol (ring A), and 
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ring B phenol O-H…O=C amide hydrogen bonds (ZIKPUG02) (Figure 45). Also, the carbonyl 
substituent on ring C is satisfied by the phenolic substituent of an adjacent luteolin molecule.97 
 
Figure 44. The structure of luteolin-isonicotinamide cocrystal (Form I) (ZIKPUG).97 
 
Figure 45. The structure of luteolin-isonicotinamide cocrystal (Form II) (ZIKPUG02).97 
 There are two known structures involving baicalein (Table 1). The structure of baicalein 
reveals three key features (RAMGOB01) (Figure 46).101 The first is the expected intramolecular 
O-H…O=C hydrogen bond. Second, a R22(10) catechol homodimer motif (ring A) between 
adjacent baicalein molecules via O-H…O hydrogen bonds is observed. Third, in the absence of 
the hydroxy substituent α to the carbonyl group on ring C (with the result that dimer formation is 
not feasible) an intermolecular O-H…O=C hydrogen bond between adjacent baicalein molecules 
is observed. 
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Figure 46. The structure of baicalein (RAMGOB01).101 
 An examination of the crystal structure of 1:1 baicalein-nicotinamide cocrystal shows the 
intramolecular hydrogen bond between the phenolic moiety on ring A and the carbonyl group on 
ring C being retained (GAZWUB) (Figure 47).102 Interestingly, the R22(10) catechol homodimer 
observed in the structure of baicalein has given way to the R22(9) heterodimer motif formed 
between the catechol moiety on ring A and the amide group of nicotinamide via phenol O-
H…O=C amide and amide N-H…O phenol hydrogen bonds. Also, the exo phenolic hydrogen 
atom of the catechol-amide dimer motif is hydrogen-bonded to Narom nicotinamide. Furthermore, 
the architecture is extended via N-H…O=C intermolecular amide C(4) chains. 
 
Figure 47. The structure of baicalein-nicotinamide cocrystal (GAZWUB).102 
 To date the only known crystal structure of naringenin is the structure itself, which 
displays an expected intramolecular ring A phenol O-H…O=C carbonyl (ring C) hydrogen bond 
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(DOLRIF). The phenolic substituents on rings A and B from two adjacent naringenin molecules 
upon hydrogen bonding form a unique R22(24) supramolecular homosynthon. In the absence of 
the hydroxy substituent α to the carbonyl group on ring C, the remaining phenolic substituent on 
ring B caps the carbonyl group, thus extending the homosynthons into 1-D ribbons (Figure 
48).103 
 
Figure 48. The structure of naringenin (DOLRIF).103 
 There are four known structures involving hesperetin (see Table 1). Anhydrous 
hesperetin displays common structure defining hydrogen bonds to those seen in luteolin 
hemihydrate and naringenin, wherein the expected intramolecular (O-H…O=C) hydrogen bond 
along with the phenolic substituent on ring A being hydrogen-bonded to the carbonyl group on 
ring C (flavonoid capping motif) is observed, which leads to the formation of 1-D chains 
(YEHROS) (Figure 49 a).104 Similarly, in the structure of hesperetin monohydrate the expected 
intramolecular and intermolecular phenol O-H…O=C carbonyl hydrogen bonds have been 
retained leading to the formation of 1-D chains (FOYTOC) (Figure 49 b).105 Furthermore, the 
water molecules act as a bridge between two adjacent 1-D chains via ring A phenol O-H…O 
water and water O-H…O phenol (ring B) hydrogen bonds. The hydroxy substituent α to the 
methoxy group on ring B in hesperetin monohydrate is involved in hydrogen bonding, in contrast 
to the anhydrous hesperetin. 
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Figure 49. The structure of: (a) hesperetin (YEHROS);104 and (b) hesperetin monohydrate 
(FOYTOC).105 
 In the structure of genistein a combination of two phenol O-H…O phenol (between 
substituents on rings A and B) and two ring A phenol O-H…O=C carbonyl (ring C) (flavonoid 
capping motif) hydrogen bonds between four adjacent genistein molecules leads to the formation 
of a R44(42) supramolecular motif, which are interconnected by a R44(22) motif (GENIST) (Figure 
50).106 
 
Figure 50. The structure of genistein (GENIST).106 
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 The genistein-isonicotinamide (1:2) cocrystal retains the intramolecular hydrogen bonds, 
whereas the intermolecular flavonoid capping motif is absent (YIKRAN) (Figure 51).107 The 
amide-amide homodimers are interconnected by discrete phenol O-H…Narom hydrogen bonds 
leading to the formation of 1-D chains. Additionally, an extended architecture is formed via anti-
amide N-H…O phenol (rings A and B) intermolecular interactions. In contrast, the amide-amide 
dimer is absent in genistein-nicotinamide (1:1) monohydrate, and has been replaced by amide N-
H…O phenol (ring B) hydrogen bonds (ZIKPIU). Furthermore, ring A phenol O-H…Narom 
intermolecular interactions lead to the formation of 1-D chains (Figure 52).97 The remaining 
phenolic substituent on ring B is hydrogen-bonded to a water molecule (which is a reflection of 
the reduced stoichiometry of the coformer), and the 3-D supramolecular architecture is 
assembled via water O-H…O=C amide and water O-H…O phenol hydrogen bonds. 
 
Figure 51. The structure of genistein-isonicotinamide cocrystal (YIKRAN).107 
 
Figure 52. The structure of genistein-nicotinamide monohydrate (ZIKPIU).97 
 The diasteriomeric flavanols (+)-(2R,3S)-catechin and (-)-(2R,3R)-epicatechin are the 
naturally occurring forms and are also commonly found functionalized as the gallate ester. An 
important feature of the structure of epicatechin is the R44(8) hydroxy tetramer formed via O-
H…O hydrogen-bonded interactions between three phenolic moieties (rings A and B) and one 
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hydroxy substituent (ring C) on epicatechin (COWHUR) (Figure 53).108 The remaining phenolic 
substituent on ring B is hydrogen bonded to the oxygen atom of ring C. In comparison, the only 
stable hydrate seen for catechin (4.5) is the one in which three of the hydroxy substituents 
interact with water molecules, whereas the remaining two hydroxy substituents are involved in 
phenol O-H…O phenol hydrogen bonds (LUXWOR).109 Cocrystal formation in epicatechin-
caffeine dihydrate (WUSFIA)110 and catechin-caffeine trihydrate (OZIDUX)111 molecular 
complexes is achieved via ring A hydroxy O-H…O=C caffeine hydrogen bonds, whereas all other 
hydrogen bond donors and acceptors on catechin and the coformer caffeine are satisfied by the 
water molecules via multiple O-H…O hydrogen bonds (Figure 54). 
 
Figure 53. The structure of epicatechin (COWHUR).108 
 
Figure 54. The structure of epicatechin-caffeine dihydrate (WUSFIA).110 
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 There are two known hydrated molecular complexes of catechin gallate with caffeine. 
The first is the 1:2:4 catechin gallate:caffeine:water molecular complex, wherein the expected 
motif (phenol O-H…Narom) is not observed (OZIDIL). Instead cocrystal formation is 
accomplished via rings A and B phenol O-H…O=C caffeine hydrogen bonds, whereas the water 
molecules are interacting with all the hydrogen bond donor/acceptor sites on both catechin 
gallate and caffeine molecules (Figure 55).111 In comparison, the 2:4:6 epicatechin 
gallate:caffeine:water molecular complex displays the expected ring B phenol O-H…Narom and 
ring A phenol O-H…O=C caffeine intermolecular interactions (WUSFOG) (Figure 56).110 Also, 
π-π interactions are prevalent in this supramolecular architecture. The water molecules are 
satisfying the remaining hydrogen bond donors/acceptors in the system. 
 
Figure 55. The structure of catechin gallate:caffeine:water (1:2:4) molecular complex 
(OZIDIL).111 
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Figure 56. The structure of epicatechin gallate:caffeine:water (2:4:6) molecular complex 
(WUSFOG).110 
 There are twelve structures involving epigallocatechin gallate (EGCG) (see Table 1). 
Focussing initially on the structure of EGCG by itself, there are multiple characteristic phenol O-
H…O phenol hydrogen bonds (Figure 57).112 Similarly, EGCG monohydrate also displays 
multiple phenol O-H…O phenol hydrogen bonds, wherein one of the phenolic substituent is 
hydrogen-bonded to a water molecule, while another is hydrogen bonding with the carbonyl of 
the ester functional group (BONKOF) (Figure 58).113 
 
Figure 57. The structure of epigallocatechin gallate.112 
 46 
 
Figure 58. The structure of epigallocatechin gallate monohydrate (BONKOF).113 
 Epigallocatechin gallate (EGCG) has seven hydrated cocrystals, the most seen for any of 
the flavonoids. This can be a direct consequence of the presence of multiple hydroxy substituents 
on EGCG when compared to the other flavonoids. Of the three known hydrated cocrystals of 
EGCG with caffeine [trihydrate (RUNDUA),114 hexahydrate (BONKIZ)113 and heptahydrate 
(VEQTES)115], the trihydrate and hexahydrate display the expected ring B phenol O-H…Narom 
and ring A phenol O-H…O=C caffeine motifs, where the water molecules are interacting with the 
remaining hydrogen bond donors/acceptors on EGCG and caffeine molecules (Figure 59). In the 
case of the heptahydrate complex, although the expected ring B phenol O-H…Narom hydrogen-
bonded interactions are observed, phenol O-H…O=C caffeine interactions have been displaced by 
water O-H…O=C caffeine hydrogen bonds, and water molecules are satisfying the remaining 
hydrogen bond donors and acceptors in the system (Figure 60).115 
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Figure 59. The structure of EGCG:caffeine:water (1:2:3) molecular complex (RUNDUA).114 
 
Figure 60. The structure of EGCG:caffeine:water (1:1:7) molecular complex (VEQTES).115 
 In both the hydrated cocrystals of EGCG with nicotinamide (1:1) [pentahydrate 
(VEQTIW)115 and nonahydrate112], cocrystal formation is driven via expected phenol O-
H…Narom, phenol O-H…O=C nicotinamide, and nicotinamide N-H…O phenol hydrogen bonds, 
where the water molecules are satisfying the remaining hydrogen bond donors and acceptors 
(Figure 61). The structure of 1:1 EGCG-isonicotinamide pentahydrate has the same hydrogen 
bonded motifs as found in the hydrated EGCG-nicotinamide cocrystals (Figure 62).112 
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Figure 61. The structure of EGCG-nicotinamide (1:1) nonahydrate.112 
 
Figure 62. The structure of EGCG-isonicotinamide (1:1) pentahydrate.112 
 The structures of both racemic (NELRUR) and non-racemic forms (FAFXUF) of 
pinoresinol display similar supramolecular motifs, i.e. phenol O-H…O phenol and phenol O-
H…O cyclic hydrogen bonds.116,117 Despite having the same kinds of intermolecular interactions, 
the two structures are very different from each other. (+)-Pinoresinol displays orthogonal chains 
(Figure 63),116 whereas the structure of racemic pinoresinol resembles a 2-D sheet (Figure 64).117 
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Figure 63. The structure of (+)-pinoresinol (FAFXUF).116 
 
Figure 64. The structure of racemic pinoresinol (NELRUR).117 
 There are five known structures involving podophyllotoxin (see Table 1) which by itself 
exists as two forms. The first one does not display any discernible hydrogen bonds or short 
contacts (PACSUH).118 However, the second form shows infinite 1-D chains formed via head-to-
tail alcohol O-H…O methoxy hydrogen-bonded interactions (PACSUJ) (Figure 65).119 
 
Figure 65. The structure of podophyllotoxin (PACSUJ).119 
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2.2.1 Common features observed for polyphenols 
Some common structural features that are observed in the structures of different polyphenols 
including coumarin (8), stilbenes (9-10), flavonoids (11-21) and lignans (22-23) along with the 
robust intermolecular interactions, Table 3, which are present in these crystal structures are 
outlined in this section. 
Table 3. The most common intra- and intermolecular interactions observed in the polyphenols 
have been organized in two categories: (i) phenols as donors; and (ii) phenols as acceptors. 
Type of Interaction Structure Hydrated 
structures 
Cocrystals Hydrated 
cocrystals 
Salts Solvates 
Phenols as donors 
O
H
O
H  
9, 15, 16, 
18, 19, 
21, 22 
12, 14, 17, 
19, 21 
11(2), 12, 
13, 14 
19, 21(3) 17(2) 12(2), 
21 
O
H
O
 
15, 16, 
17, 18 
12(2), 14, 
17 
11(2), 
12(2), 
14(2), 17, 
18 
12, 18, 
19(2), 
20(2), 21 
12, 
17(2) 
12(2), 
13 
O
H
O
 
11(2), 19      19(2), 
22(2) 
O
H
O
H  
19 19  19  12, 
19(2) 
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O
H
N
 
  12, 13, 
14(2), 15, 
17, 18 
18, 20, 
21(6) 
 12(2), 
13, 19 
O
H
O
N
H
H
 
  10, 11, 12, 
13, 14(2), 
15  
21(3)  13 
O
H
O
N
R
R
 
  11 19(2), 
20(2), 
21(2) 
 12 
O
H
O
O
R  
 21  20(2), 
21(2) 
 21 
O
H
O H
H  
 12(2), 17, 
19, 21 
 12, 18, 
19(2), 
20(2), 
21(5) 
12 21 
O
H
O
O
 
    9, 12, 
17(2), 
21 
 
Phenols as acceptors 
N
H
HO
O
H  
  11, 12, 13, 
14(2), 15, 
17, 18 
18, 21(2)  13 
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H O
H
O
H  
 12(2), 17, 
19, 21 
 12, 18, 
19(2), 
20(2), 
21(5) 
9, 12 21 
Numbers in brackets indicate the number of times the particular interaction is observed in the 
appropriate compound (as identified in Figure 3). 
 
 In the absence of any competing hydrogen bond donors and acceptors the primary 
intermolecular interaction observed in the structures of polyphenols with no carboxylic acid 
moieties is phenol O-H…O phenol hydrogen bonds (Table 3).75 Upon cocrystallization, the 
observed motifs for the phenolic moieties, such as phenol O-H…Narom, phenol O-H…O=C amide, 
and amide N-H…O phenol, are representative of the coformer used and the functional groups 
present in the coformers.  
 The calculated MEPs of the polyphenols reinforces the observations made based on the 
existing single crystal data that phenols can act as effective hydrogen bond donors (Figure 66). 
Also, it allows for a closer examination of the hydrogen bonding capability of the phenolic 
substituents on rings A and B of the flavonoids. There is a ∆E difference of 3-18 kJ mol-1 
between the best hydrogen bond donor on ring A and B for most of the flavonoids (11-13, 16-18, 
20-21), which suggests that there is no real selectivity in hydrogen bonds between the two rings, 
and cocrystallization can occur via either end of the molecule. In the majority of cases with 
flavonoids cocrystal formation is driven via hydrogen bonds involving the phenolic groups on 
either one or both A and B rings with the coformer. This is even seen for luteolin (14) which has 
a large ∆E difference of 58 kJ mol-1. 
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Figure 66. Calculated molecular electrostatic potentials (kJ mol-1) for the polyphenols. Blue = 
positive potential, red = negative potential. 
 Flavonoids with the hydroxy group α to the carbonyl substituent on ring C (11-13) have a 
tendency to form a R22(10) flavonoid dimer motif (Figure 67 a), as has been commonly observed 
in the myriad of structures containing quercetin (12) and fisetin (13). Myricetin (11) is an 
exception to this since both its cocrystals do not exhibit this dimer motif. In contrast, in 14-17 the 
absence of the hydroxy group α to the carbonyl substituent on ring C means the dimer motif 
cannot be formed and instead the carbonyl substituent is usually capped by the phenolic 
substituent of an adjacent flavonoid molecule (Figure 67 b). This motif is commonly observed in 
the structures containing luteolin (14), baicalein (15), naringenin (16), and hesperetin (17), the 
exceptions being the cocrystal of baicalein with nicotinamide and the two salts of hesperetin with 
zwitterionic nicotinic and isonicotinic acids. 
O
O
O H
O
O
O H
O
O
OH
O
H
O
H
O
O
H
O
H
O
OH
R
 
Figure 67. Common hydrogen-bonded motifs observed in flavonoids: flavonoid dimer motif 
(top) and flavonoid capping motif (bottom). 
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 Another common structural feature observed in the isonicotinamide cocrystals of 
flavonoids with a catechol moiety on the ring B backbone (quercetin, fisetin, and luteolin), is the 
formation of the R22(10) supramolecular catechol homodimer, where the dimer is flanked on both 
sides by two R33(8) phenol-amide heterodimers formed via phenol O-H…O=C amide and amide 
N-H…O phenol hydrogen bonds (Figure 68). This four component supramolecular assembly 
between two catechol moieties and two isonicotinamide molecules can also be described by the 
R44(18) graph set. 
 
Figure 68. The ‘flanked dimer’ motif commonly observed in the isonicotinamide cocrystals of 
flavonoids containing the catechol moiety. 
 Knowledge of the structural chemistry of hydrates of organic molecules can provide 
insight into the tendency of these molecules to form cocrystals.120-122 There have been a variety 
of theories postulated to explain hydrate formation for organic molecules. Thus, hydrates are 
more likely to form for: (a) a low hydrogen bond donor/hydrogen bond acceptor ratio;123 (b) 
charged compounds;124 (c) multiple counts of a functional group;124 (d) high molecular weight 
compounds;125 and (e) spatial constraints in hydrogen bonding.125 In addition, the role of 
hydrates in crystal engineering have been recently examined for a wide variety of 
supramolecular synthons.66 Analysis of the available single crystal data for phenolic acids (1-7) 
and polyphenols (8-23) indicates that further structural data are required to rationalize which 
hydrate formation theories apply for these classes of compounds. 
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3. Vitamins 
Vitamins are essential organic compounds that are required by the human body as they are not 
produced by humans in sufficient quantities.126 They are essential for metabolism and are usually 
obtained from natural sources.127 Although they are readily available over the counter and are 
easily patentable,126,127 they have not been extensively used as coformers in cocrystallization. A 
synergistic approach to cocrystallization of vitamins with other APIs can not only help improve 
the physicochemical properties of APIs, but also tap into the possibility of developing dual drugs 
with multiple benefits. Eleven different molecules have been explored in this category, of which 
two are vitamin A (24-25), five vitamin B (26-29, 33), one vitamin C (30), two vitamin D (31-
32), and one vitamin K (34) (Figure 4). Nicotinamide and nicotinic acid (vitamin B3 and 
derivative) have been extensively used in cocrystallization and their structural chemistry 
reviewed.128 
 Focusing initially on the aldehyde containing molecule retinal, there are five distinct solid 
state structures of retinal known, differing in the cis/trans conformations at the multiple alkene 
moieties. Of the five stereoisomers, four have no discernible hydrogen bonds in the architecture 
and are governed by weak C-H…O=C aldehyde intermolecular interactions (CRETAL01, 
CRETAL10, RETNLA10 and TRETAL01),129-132 although in one case, the supramolecular 
architecture is assembled via aldehyde C-H…O=C aldehyde hydrogen-bonded homodimer motif 
(FAHNEH) (Figure 69).133 These interactions are not uncommon as there are over 200 reported 
examples in the CSD of the aldehyde-aldehyde homodimer.39,40 
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Figure 69. The structure of 9-cis-retinal (FAHNEH).133 
 The carboxylic acid derivative of vitamin A is retinoic acid and there are three isomers of 
the structure of retinoic acid (TUDSIU, VITAAC01 and VITAAC10),134,135 which can again be 
attributed to the presence of differing cis/trans conformations at the multiple alkene moieties. All 
isomers display an expected acid-acid homodimer via O-H…O=C hydrogen-bonded interactions 
(Figure 70).135 The all trans-isomer has been crystallized with the plasma protein transthyretin.136 
 
Figure 70. The structure of retinoic acid (VITAAC01).135 
 Riboflavin (vitamin B2) is a molecule that combines hydroxy functional groups with 
nitrogen containing heterocyclic rings and therefore is capable of very diverse hydrogen-bonded 
interactions. The structure of 1:1 riboflavin-adenine trihydrate (ADRBFT10) reveals that 
supramolecular assembly occurs via three key intermolecular interactions: (a) riboflavin N-H…N 
adenine; (b) adenine N-H…O=C riboflavin; and (c) adenine N-H…N riboflavin hydrogen bonds, 
all of which involve imidazole (Figure 71).137These interactions between riboflavin and adenine 
molecules resemble a Hoogsteen base pair.138 The water molecules and the hydroxy substituents 
on riboflavin interact within themselves to complete the hydrogen-bonded extended network. 
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Figure 71. The structure of 1:1 riboflavin-adenine trihydrate (ADRBFT10).137 
 The hydrogen-bonded network in 1:1 riboflavin-5'-bromo-5'-deoxyadenosine trihydrate 
(RIBBAD) is similar to that observed in riboflavin-adenine trihydrate.  Hoogsteen base pair138 
formation takes place via two intermolecular interactions: (a) deoxyadenosine N-H…O=C 
riboflavin; and (b) riboflavin N-H…N deoxyadenosine (imidazole) (Figure 72).139 Other key 
hydrogen bonds include deoxyadenosine N-H…O riboflavin (alcohol) and deoxyadenosine 
(alcohol) O-H…O=C riboflavin, in which water molecules are hydrogen-bonded with the 
remaining donors and acceptors. 
 
Figure 72. The structure of 1:1 riboflavin-5'-bromo-5'-deoxyadenosine trihydrate (RIBBAD).139 
 There is only one structure reported to date for pantothenic acid which is with the 
zwitterionic amino acid L-lysine (BACWUX10),140 and a wide diversity of intermolecular 
interactions are observed in this architecture. 
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 Pyridoxine (vitamin B6) consists of the hydroxy and the pyridyl functional groups, hence 
it is capable of acting as both a hydrogen bond donor and acceptor. Anhydrous pyridoxine 
displays an infinite 1-D chain formed by head-to-tail hydrogen-bonded interactions between the 
pyridyl nitrogen atom and the hydroxy group in the para position (BITZAF) (Figure 73).141 An 
extended architecture is formed via meta position hydroxy groups hydrogen bonding with each 
other, whereas the remaining phenolic substituent is hydrogen-bonded in an intramolecular 
fashion to the para-hydroxyl group. 
 
Figure 73. The structure of pyridoxine (BITZAF).141 
 Cocrystallizing pyridoxine with a strong hydrogen bond donor such as picric acid (1:1) 
leads to complete proton transfer from picric acid to the pyridyl nitrogen atom of pyridoxine 
(CELMUC),142 which is indicative of another dimension to the variable hydrogen-bonded 
chemistry of pyridoxine. Upon proton transfer all previous motifs are broken with the only 
exception being the retention of the intramolecular hydrogen bond between the phenolic 
substituent and the para-hydroxy group (Figure 74). 
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Figure 74. The structure of pyridoxinium picrate (CELMUC).142 
 Biotin reveals the presence of a stable R22(8) acid-amide dimer as the hydrogen-bonded 
interaction for both carboxylic acids groups (BIOTIN01). Their presence, at opposite ends of the 
molecule, give rise to head-to-tail interactions and the formation of infinite 1-D chains (Figure 
75).143 These chains are linked to each other via multiple imidazole N-H…O=C acid hydrogen 
bonds. 
 
Figure 75. The structure of biotin (BIOTIN01).143 
 An examination of the structures of D-isoascorbic acid (IASCOR10) (Figure 76)  
144 and L-ascorbic acid (LASCAC12) (Figure 77)145 reveals that identical hydrogen bonds 
between the hydroxy group and the enediol moiety (alcohol O-H…O alcohol and alcohol O-
H…O=C enediol) are observed in both the compounds. Despite the similar intermolecular 
interactions in the solid-state, the two supramolecular architectures derived from the 
diastereomeric compounds are different from each other. 
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Figure 76. The structure of D-isoascorbic acid (IASCOR10).144 
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Figure 77. The structure of L-ascorbic acid (LASCAC12).145 
 Cholecalciferol (vitamin D3) is a chemically and physically unstable vitamin due to the 
presence of the unstable conjugated triene group that is capable of undergoing topochemical 
reactions.146 The structure of cholecalciferol displays hydrogen-bonded alcohol O-H…O alcohol 
C(2) catemeric chains (CHOCAL) (Figure 78).147 
 
Figure 78. The structure of cholecalciferol (CHOCAL).147 
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 A change is observed in the supramolecular synthons upon the cocrystallization of 
cholecalciferol with coformers containing alcohol functional groups such as cholesterol 
(RINTIT) and cholestanol (RINTOZ).146 The stable hydrogen bonded alcohol R44(8) tetramers are 
observed for both the 1:1 cocrystals, wherein the O-H moieties of both cholecalciferol and the 
coformers arrange in a head-to-tail fashion, thus replacing the hydrogen-bonded chains in 
cholecalciferol alone (Figure 79).146 
 
Figure 79. The structure of 1:1 cholecalciferol-cholesterol cocrystal (RINTIT).146 
 Ergocalciferol (vitamin D2) is very similar in molecular structure to cholecalciferol. 
Consequently, the structure of ergocalciferol shows the similiar structural features to that of 
cholecalciferol with infinite 1-D chains propagated by alcohol O-H…O alcohol hydrogen bonds 
(ERGCAL10) (Figure 80). 148 
 
Figure 80. The structure of ergocalciferol (ERGCAL10). 148 
 A 1:1 lumisterol2 : 6-s-trans-vitamin D2 (ergocalciferol) composition is also known as 
vitamin D1, and the structure of this cocrystal retains similar alcohol C(2) catemeric chains to 
those observed in ergocalciferol alone (SEQNIL) (Figure 81). 149 
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Figure 81. The structure of vitamin D1 (SEQNIL).149 
 Folic acid dihydrate displays two key intermolecular interactions: (a) acid-amide R22(8) 
heterodimer; and (b) acid-2-aminopyridine R22(8) heterodimer (Figure 82).150 The water 
molecules are satisfying the remaining hydrogen bond donors and acceptors. 
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Figure 82. Hydrogen bonding motifs present in the folic acid dihydrate.150 
 The two polymorphs of menadione (IVEJUO and IVEJUO03) display no discernible 
hydrogen bonds in the crystalline lattice, and the supramolecular architecture is assembled via 
weak C-H…O=C contacts along with π-π stacking present (Figure 83).151,152 
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Figure 83. The structure of menadione (IVEJUO).151 
 The diverse chemical functionalities seen in the vitamins, allied with the few examples of 
vitamin containing cocrystals, means that a systematic analysis of their solid state behavior is 
presently not possible. 
4. Tuning physicochemical properties 
Although the cocrystallization of nutraceuticals from a pharmaceutical perspective is a relatively 
new field, there have been some important studies that have explored the possibility of 
improving key physicochemical properties such as physical stability,51,64,87,88,92,97,146 
solubility61,62,87,88,96,112 and bioavailability96,112 of nutraceuticals, as well as of APIs. A summary 
of these studies is provided in Tables 4-5 and case studies discussed in more detail below.  
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Table 4. Altered physicochemical properties of cocrystals of phenolic acids.a 
Molecule Coformer Observations 
Gallic acid (S)-Oxiracetam51 Improved physical stability over both time and relative humidity. 
 (±)-Oxiracetam51 Improved physical stability over both time and relative humidity. 
 Isoniazid52 Difference in proton conduction upon dehydration (x 103). 
 Pyrazine-2-carboxamide.H2O61 Increased aqueous solubility (x 1.3). 
Protocatechuic acid (S)-Oxiracetam51 Altered physical stability over both time and relative humidity. 
 (±)-Oxiracetam51 Altered physical stability over both time and relative humidity. 
Vanillic acid Pyrazine-2-carboxamide61 Increased aqueous solubility (x 2.2). 
 Ethenzamide62 Improved equilibrium solubility (x 4.5) and intrinsic dissolution rate (x 1.7). 
 Andrographolide64 Improved chemical stability of andrographolide. 
a relative to the nutraceutical 
 
Table 5. Altered physicochemical properties of stilbene and flavonoid cocrystals.a 
Molecule Coformer Observations 
Pterostilbene Piperazine87 Improved physical stability over both time and relative humidity; increased 
aqueous solubility (x 6). 
 Glutaric acid87 Improved physical stability over both time and relative humidity. 
 Caffeine (Form I) 88 Improved physical stability over both time and relative humidity; increased 
solubility (x 27). 
 Carbamazepine88 Improved physical stability over both time and relative humidity; decreased 
solubility (x 2.5). 
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Myricetin Piracetam92 Reduced thermal stability. 
Quercetin Isonicotinamide96 Increased solubility (x 5); increased bioavailability (x 6), reaches systemic 
circulation faster. 
 Theobromine.2H2O66,96  Improved solubility; increased bioavailability (x 10), slower elimination from 
the body. 
 Caffeine96 Increased solubility (x 14); increased bioavailability (x 3). 
 Caffeine.CH3OH96 Increased solubility (x 8); increased bioavailability (x 4). 
Fisetin Isonicotinamide97 Reduced thermal stability. 
 2Nicotinamide.0.5C2H5OH97 Reduced thermal stability. 
 Nicotinamide97 Reduced thermal stability. 
Luteolin Isonicotinamide (Forms I and II) 
97 
Reduced thermal stability. 
Genistein Nicotinamide.H2O97 Reduced thermal stability. 
Epicatechin gallate 
(ECG) 
2Caffeine.3H2O110Error! Bookmark 
not defined. 
Improved aqueous stability. 
Epigallocatechin  Nicotinamide.9H2O112 Decreased solubility (x 8); decreased bioavailability (45%). 
gallate (EGCG) Isonicotinamide.5H2O112 Decreased solubility (x 17); decreased bioavailability (40%). 
 Isonicotinic acid.3H2O112 Decreased solubility (x 22); increased bioavailability (Frel = 1.37). 
 Isonicotinic acid112 Decreased solubility (x 19); increased bioavailability (Frel = 1.05). 
a relative to the nutraceutical 
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 Physicochemical properties such as solubility and dissolution rate were evaluated for 
cocrystals of vanillic acid (3) with the analgesic drug ethenzamide in 10% ethanol-water (v/v). 62 
There is a 4.5 fold improvement in the equilibrium solubility of 1:1 ethenzamide:vanillic acid 
cocrystal (7.12 mg mL-1) in comparison to ethenzamide (1.58 mg mL-1). Also, the intrinsic 
dissolution rate (IDR) of the cocrystal is 1.7 times (7.55 x 10-3 mg cm-2 min-1) that of 
ethenzamide alone (4.40 x 10-3 mg cm-2 min-1). Cocrystals containing gallic acid (1) and the API 
(S)-oxiracetam / (RS)-oxiracetam show much improved hygroscopic stability over prolonged 
periods of time relative to the API.51 The (S) enantiomer is stable up to 75% relative humidity 
(RH) for eight weeks, whereas racemic oxiracetam is stable up to 87% RH for eight weeks. In 
comparison, gallic acid cocrystals with either enantiopure or racemic oxiracetam are stable up to 
98% RH for eight weeks. This significant enhancement in the hygroscopic stability has been 
attributed to the formation of a more extended 3D hydrogen bonded framework in these 
cocrystals. 
 Pterostilbene (10), a nutraceutical having poor aqueous solubility (21 µg mL-1) was 
cocrystallized with four pharmaceutically acceptable coformers, viz caffeine, carbamazepine, 
glutaric acid and piperazine, to improve its aqueous solubility.87,88 Although the cocrystals with 
caffeine, carbamazepine and piperazine resulted in lower solubility of the coformers, the 
concentration of pterostilbene achieved in solution was increased 27-fold for the cocrystal with 
caffeine, whereas it was lowered 2.5-fold for the cocrystal with carbamazepine. All the 
cocrystals in this study displayed remarkable physical stability, with respect to increasing RH 
and temperature over specified time periods of up to 8 weeks, in comparison to the individual 
coformers. 
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 Quercetin (12), one of the most abundant flavonoids in the plant kingdom, is well known 
for its numerous therapeutic bioactivities in vitro. However, its efficacy is limited in vivo due to 
the poor bioavailability and low solubility. The physicochemical properties (solubility and 
bioavailability) of four cocrystals of quercetin with GRAS coformers (isonicotinamide, 
theobromine and caffeine) were examined in 50% ethanol-water (v/v), and it was found that each 
of these cocrystals exhibited superior solubility compared to quercetin dihydrate (Table 4). 96 It 
was hypothesized that an improvement in solubility would translate into enhanced systemic 
absorption of quercetin, and the experimental results validated this hypothesis as up to a 10-fold 
improvement in the bioavailability was observed in comparison to quercetin dihydrate (see Frel 
values in Table 6). This study suggests that cocrystallization can be a potential solution to the 
solubility and bioavailability problems that prevent 12 from being used as an effective treatment 
option for its numerous therapeutic bioactivities. 
Table 6. Solubility and bioavailability (Frel) of 12 and its cocrystals.96 
 12 12:Isonicotinamide 12:Caffeine.MeOH 12:Caffeine 12:Theobromine.2H2O 
Solubility 
(mg mL-1) 
0.267 1.22 2.018 3.627 0.326 
Frel 1.00 5.46 4.01 2.57 9.93 
 
 Five cocrystals of the flavonoids fisetin (13), luteolin (14) and genistein (18), natural 
polyphenolic compounds of pharmaceutical interest, were synthesized with nicotinamide and 
isonicotinamide as coformers.97 An examination of the thermal stability of 13:isonicotinamide 
and 14:isonicotinamide (Forms I and II) revealed that the cocrystals were stable up to 230, 250 
and 260 ºC, respectively. The solvated 13:nicotinamide and 18:nicotinamide exhibit loss of 
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solvent molecules above 110 and 80 ºC, respectively, with the desolvated 13:nicotinamide 
cocrystal being further stable up to 180 ºC. The melting point of these cocrystals lies in between 
that of the flavonoid and the coformer, and the authors refer to this as a reduction in thermal 
stability with respect to the flavonoid. 
 Cholecalciferol/vitamin D3 (31) is a chemically and physically unstable vitamin used for 
the treatment of osteomalacia and osteoporosis.153 The unstable conjugated triene group 
undergoes topochemical reactions, as a result it has to be stored under controlled conditions and 
is rarely formulated in solid dosage form. Two cocrystals of 31 with pharmaceutically acceptable 
steroids, cholesterol and cholestanol, have been prepared utilizing O-H…O hydrogen bonds.146 
These isostructural cocrystals are topochemically stable and have a far superior chemical and 
physical stability compared to 31 alone. An increased packing coefficient (Ck = 0.702 and 0.696 
for 31:cholesterol and 31:cholestanol, respectively) and density (1.06 and 1.05 g/cm3 for 
31:cholesterol and 31:cholestanol, respectively) is responsible for imparting increased 
conformational stability to the cocrystals. Also, the two cocrystals show improved thermal 
stability (by 40 ºC), and physical stability over both time and RH. These results may encourage 
the future development of novel forms of this important bioactive vitamin and facilitate its 
widespread use in nutrition industries. 
5. Summary and Outlook 
Pharmaceutical cocrystallization is an important and rapidly expanding field with the objective 
of favorably altering the physical properties of APIs. The choice of the coformer is crucial in 
cocrystallization not only for synthon compatibility, but also because properties of the obtained 
multi-component materials are generally strongly influenced by the coformer. Usually the 
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accepted coformers are chosen from the GRAS or EAFUS lists. Nutraceuticals are a class of 
compounds that are readily available over the counter, are easily patentable, and have a wide 
range of beneficial properties (e.g. anti-oxidants), however, they are yet to be utilized extensively 
as coformers in cocrystallization. In this review, we have detailed the different forms of 
nutraceuticals that have been explored to date and analyzed the different inter- and 
intramolecular interactions involved in their solid state forms. 
 There are two categories of nutraceuticals, namely polyphenols and vitamins, of which 
polyphenols can be further subdivided into (i) phenolic acids and (ii), coumarin, stilbenes, 
flavonoids and lignans. All the observed crystal structures have been divided into six categories 
(pure compounds, hydrated structures, cocrystals, hydrated cocrystals, salts, and solvates) to help 
better understand the available data and to aid in the analysis of the different motifs present in 
their solid state structures. Upon examination of the data it is observed that, relatively, phenolic 
acids have been studied in greater detail, followed by flavonoids, and the least explored are the 
vitamins. Notably, the key supramolecular motifs observed in the structures of nutraceuticals, 
either pure or in cocrystals, are entirely as expected based on established supramolecular 
synthons. For phenolic acids, which combine carboxylic acid and phenolic substituents, the acid-
acid dimer is generally seen, particularly in the absence of any competing hydrogen bond donors 
or acceptors. The phenolic substituents form O-H…O homosynthons or are hydrogen bonded to 
the acid-acid dimer. The presence of competing hydrogen bond donors and acceptors often 
disrupts the acid-acid dimer motif with hydrogen bonding occurring according to Etter’s rules. 
Flavonoids only have phenolic substituents on the backbone, and hence primarily form phenol 
O-H…O phenol homosynthons in the solid state. Addition of coformers allows a variety of 
supramolecular motifs such as phenol O-H…Narom, and phenol O-H…O=C acid/amide/ketone 
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hydrogen bonds to be exploited for cocrystallization. Vitamins have a diverse range of functional 
groups and, accordingly, their supramolecular chemistry is a direct reflection of the groups 
present. 
 A handful of studies have explored the cocrystallization of APIs with nutraceuticals with 
a view to favorably altering the physicochemical properties of APIs, such as physical stability, 
solubility, and bioavailability. Greater emphasis has been given to the thermal stability and the 
physical stability of these cocrystals over a wide range of time and humidity, with remarkable 
success being achieved in the case of gallic acid, protocatechuic acid, pterostilbene, myricetin, 
luteolin, genistein, and fisetin. The solubility and bioavailability have also been successfully 
altered for some nutraceuticals including phenolic acids, stilbenes and flavonoids. 
 The field of cocrystallization of nutraceuticals is still in its infancy. Knowledge of the 
different solid state forms of nutraceuticals and the supramolecular synthons commonly observed 
in their structures, which have been described in this review, will allow the formation of 
functional materials with targeted physicochemical properties in the future, for example, 
exploiting the anti-oxidant properties of flavonoids and other nutraceuticals. Furthermore, ionic 
cocrystals in which a salt is cocrystallized with either an organic molecule, or an organic salt, 
have received considerable attention recently,154-157 and nutraceuticals are an obvious candidate 
for this area of study. In summary, this review assesses the structural data available to date across 
a diverse range of nutraceuticals, both in pure form and in multicomponent materials, and 
identifies the persistent supramolecular features present. It provides a firm foundation for future 
studies which will ultimately enable predictive and controlled assembly of functional materials 
incorporating nutraceuticals together with APIs. 
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